Polycystic Ovarian Syndrome - Pipeline Review -





Description


Global Markets Direct’s, ‘Polycystic Ovarian Syndrome - Pipeline Review, H1 2014’, provides an overview of the Polycystic Ovarian Syndrome’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Polycystic Ovarian Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Ovarian Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. 

 

Scope

  • The report provides a snapshot of the global therapeutic landscape of Polycystic Ovarian Syndrome
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Polycystic Ovarian Syndrome and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Polycystic Ovarian Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Polycystic Ovarian Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
 
 

Reasons to Buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Polycystic Ovarian Syndrome
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Polycystic Ovarian Syndrome Overview 7
Therapeutics Development 8
Pipeline Products for Polycystic Ovarian Syndrome - Overview 8
Pipeline Products for Polycystic Ovarian Syndrome - Comparative Analysis 9
Polycystic Ovarian Syndrome - Therapeutics under Development by Companies 10
Polycystic Ovarian Syndrome - Therapeutics under Investigation by Universities/Institutes 12
Polycystic Ovarian Syndrome - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Polycystic Ovarian Syndrome - Products under Development by Companies 16
Polycystic Ovarian Syndrome - Products under Investigation by Universities/Institutes 17
Polycystic Ovarian Syndrome - Companies Involved in Therapeutics Development 18
AstraZeneca PLC 18
Euroscreen S.A. 19
Neurocrine Biosciences, Inc. 20
Merck KGaA 21
EffRx Pharmaceuticals S.A. 22
Crinetics Pharmaceuticals, Inc. 23
Polycystic Ovarian Syndrome - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
choriogonadotropin alfa - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
doxycycline - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
AZD-4901 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ESN-364 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
GnRH Antagonists - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
metformin hydrochloride - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Drugs to Inhibit GnRH Receptor for Dermatology, Hormonal Disorders, Non Malignant Disorders, Oncology and Women Health - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Kisspeptin Peptide Antagonists - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Metabolic Syndrome Program - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
KISS-1R Antagonist For Polycystic Ovarian Syndrome - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Drugs to Inhibit PAI-1 for Thromboembolic Disease, PCOS and Alopecia - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Polycystic Ovarian Syndrome - Recent Pipeline Updates 44
Polycystic Ovarian Syndrome - Dormant Projects 45
Polycystic Ovarian Syndrome - Product Development Milestones 46
Featured News & Press Releases 46
Oct 01, 2013: EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome in Paediatric Populations 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 48
Disclaimer 48